IRF3 and cancer: Specifically, mutant p53, unlike wild-type p53, interacts with TBK1 and inhibits the formation of the complexes involving TBK1, STING, and IRF3 (in vitro in various cancer lines such as MDA-MB-231, BT549, H1299, MiaPaCa-2, and A549, and in vivo in BALB/c and NOD/SCID xenografted mice) [109,110].